Clinical trial
A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or…
NCT00358956 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00358956 |
|---|---|
| Title | A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer |
| Official title | A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thyroid Cancer |
| Intervention type | Drug |
| Interventions | ZD6474 (vandetanib) |
| Enrollment | 19 |
| Start date | Aug 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | May 1, 2014 |
| First posted | Aug 1, 2006 |
| Last update posted | Jan 30, 2017 |
| Countries | Australia, Canada, Italy, Netherlands, Romania, Spain, Switzerland, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: